Savella relieves symptoms of fibromyalgia
Delivers simultaneous improvements on 3 measures of fibromyalgia1
- Pain reduction
- Improvement in patient global fibromyalgia assessment
- Improvement in physical function
Decrease in pain as early as week 1 of treatment with a stable dose in patients who reported global improvement1
Low potential for pharmacokinetic drug-drug interactions1
- Clinically important interactions may occur with lithium, epinephrine and norepinephrine, serotonergic drugs, digoxin, clonidine, clomipramine, CNS-active drugs, and MAOIs
A dual reuptake inhibitor that blocks the uptake of norepinephrine over serotonin with approximately 3 times greater potency in vitro1
Savella is effective in the management of fibromyalgia
Efficacy established in studies of adult patients who met American College of Rheumatology (ACR) criteria for fibromyalgia1
- History of widespread pain for 3 months
- Pain present at ≥11 of 18 specific tender point sites
2-measure composite responders were required to demonstrate simultaneous pain relief and global improvement vs placebo
3-measure composite responders were required to demonstrate simultaneous pain relief, global improvement, and physical function improvement vs placebo
Available in 12.5 mg, 25 mg, 50 mg, and 100 mg tablets
Week 1 titration1
Day 1
12.5 mg onceDays 2-3
25 mg/day (12.5 mg twice daily)Days 4-7
50 mg/day (25 mg twice daily)Week 2 and beyond1
Recommended dose
100 mg/day (50 mg twice daily)Dosing and administration
- Twice-daily (AM/PM) dosing with or without food1
- Taking Savella with food may improve tolerability
- Based on individual patient response, the dose may be increased to 200 mg/day (100 mg twice daily). Doses above 200 mg/day have not been studied1
- Savella should be tapered and not abruptly discontinued after extended use1
- Savella is non-narcotic and is not scheduled
No dosage adjustment needed for patients with hepatic impairment or mild renal impairment1
- Savella should be used with caution in patients with moderate renal impairment
- In patients with severe renal impairment, the maintenance dose should be reduced by 50%
- Savella is not recommended for patients with end-stage renal disease
- As with any drug, caution should be exercised in patients with severe hepatic impairment
- Savella should ordinarily not be prescribed to patients with substantial alcohol use or evidence of chronic liver disease
